Assessing the Performance of European-derived Cardiometabolic Polygenic Risk Scores in South-Asians and Their Interplay with Family History

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2023 Jul 12

PMID 37438803

Authors

Emadeldin Hassanin

Carlo Maj

Hannah Klinkhammer

Peter Krawitz

Patrick May

Dheeraj Reddy Bobbili

Affiliations

Soon will be listed here.

Abstract

Background & Aims: We aimed to assess the performance of European-derived polygenic risk scores (PRSs) for common metabolic diseases such as coronary artery disease (CAD), obesity, and type 2 diabetes (T2D) in the South Asian (SAS) individuals in the UK Biobank. Additionally, we studied the interaction between PRS and family history (FH) in the same population.

Methods: To calculate the PRS, we used a previously published model derived from the EUR population and applied it to the individuals of SAS ancestry from the UKB study. Each PRS was adjusted according to an individual's genotype location in the principal components (PC) space to derive an ancestry adjusted PRS (aPRS). We calculated the percentiles based on aPRS and stratified individuals into three aPRS categories: low, intermediate, and high. Considering the intermediate-aPRS percentile as a reference, we compared the low and high aPRS categories and generated the odds ratio (OR) estimates. Further, we measured the combined role of aPRS and first-degree family history (FH) in the SAS population.

Results: The risk of developing severe obesity for SAS individuals was almost twofold higher for individuals with high aPRS than for those with intermediate aPRS, with an OR of 1.95 (95% CI = 1.71-2.23, P < 0.01). At the same time, the risk of severe obesity was lower in the low-aPRS group (OR = 0.60, CI = 0.53-0.67, P < 0.01). Results in the same direction were found in the EUR data, where the low-PRS group had an OR of 0.53 (95% CI = 0.51-0.56, P < 0.01) and the high-PRS group had an OR of 2.06 (95% CI = 2.00-2.12, P < 0.01). We observed similar results for CAD and T2D. Further, we show that SAS individuals with a familial history of CAD and T2D with high-aPRS are associated with a higher risk of these diseases, implying a greater genetic predisposition.

Conclusion: Our findings suggest that CAD, obesity, and T2D GWAS summary statistics generated predominantly from the EUR population can be potentially used to derive aPRS in SAS individuals for risk stratification. With future GWAS recruiting more SAS participants and tailoring the PRSs towards SAS ancestry, the predictive power of PRS is likely to improve further.

Citing Articles

Use of Polygenic Risk Score for Prediction of Heart Failure in Cancer Survivors.

Soh C, Xiang R, Takeuchi F, Marwick T JACC CardioOncol. 2024; 6(5):714-727.

PMID: 39479322 PMC: 11520200. DOI: 10.1016/j.jaccao.2024.04.010.

Generalizability of polygenic prediction models: how is the R defined on test data?.

Staerk C, Klinkhammer H, Wistuba T, Maj C, Mayr A BMC Med Genomics. 2024; 17(1):132.

PMID: 38755654 PMC: 11100126. DOI: 10.1186/s12920-024-01905-8.

References

Mars N, Lindbohm J, Briotta Parolo P, Widen E, Kaprio J, Palotie A . Systematic comparison of family history and polygenic risk across 24 common diseases. Am J Hum Genet. 2022; 109(12):2152-2162. PMC: 9748261. DOI: 10.1016/j.ajhg.2022.10.009. View

Hao L, Kraft P, Berriz G, Hynes E, Koch C, Korategere V Kumar P . Development of a clinical polygenic risk score assay and reporting workflow. Nat Med. 2022; 28(5):1006-1013. PMC: 9117136. DOI: 10.1038/s41591-022-01767-6. View

Yang S, Zhou X . Accurate and Scalable Construction of Polygenic Scores in Large Biobank Data Sets. Am J Hum Genet. 2020; 106(5):679-693. PMC: 7212266. DOI: 10.1016/j.ajhg.2020.03.013. View

Choi S, OReilly P . PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience. 2019; 8(7). PMC: 6629542. DOI: 10.1093/gigascience/giz082. View

Barnett A, Dixon A, Bellary S, Hanif M, OHare J, Raymond N . Type 2 diabetes and cardiovascular risk in the UK south Asian community. Diabetologia. 2006; 49(10):2234-46. DOI: 10.1007/s00125-006-0325-1. View

Li Y, Willer C, Sanna S, Abecasis G . Genotype imputation. Annu Rev Genomics Hum Genet. 2009; 10:387-406. PMC: 2925172. DOI: 10.1146/annurev.genom.9.081307.164242. View

Hodgson S, Huang Q, Sallah N, Griffiths C, Newman W, Trembath R . Integrating polygenic risk scores in the prediction of type 2 diabetes risk and subtypes in British Pakistanis and Bangladeshis: A population-based cohort study. PLoS Med. 2022; 19(5):e1003981. PMC: 9119501. DOI: 10.1371/journal.pmed.1003981. View

Fritsche L, Ma Y, Zhang D, Salvatore M, Lee S, Zhou X . On cross-ancestry cancer polygenic risk scores. PLoS Genet. 2021; 17(9):e1009670. PMC: 8445431. DOI: 10.1371/journal.pgen.1009670. View

Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L . The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. Nucleic Acids Res. 2022; 51(D1):D977-D985. PMC: 9825413. DOI: 10.1093/nar/gkac1010. View

10.

Bycroft C, Freeman C, Petkova D, Band G, Elliott L, Sharp K . The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018; 562(7726):203-209. PMC: 6786975. DOI: 10.1038/s41586-018-0579-z. View

11.

Khera A, Chaffin M, Aragam K, Haas M, Roselli C, Choi S . Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018; 50(9):1219-1224. PMC: 6128408. DOI: 10.1038/s41588-018-0183-z. View

12.

Fahed A, Wang M, Homburger J, Patel A, Bick A, Neben C . Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat Commun. 2020; 11(1):3635. PMC: 7441381. DOI: 10.1038/s41467-020-17374-3. View

13.

Lambert S, Gil L, Jupp S, Ritchie S, Xu Y, Buniello A . The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. Nat Genet. 2021; 53(4):420-425. PMC: 11165303. DOI: 10.1038/s41588-021-00783-5. View

14.

Curtis D . Polygenic risk score for schizophrenia is more strongly associated with ancestry than with schizophrenia. Psychiatr Genet. 2018; 28(5):85-89. DOI: 10.1097/YPG.0000000000000206. View

15.

Visscher P, Wray N, Zhang Q, Sklar P, McCarthy M, Brown M . 10 Years of GWAS Discovery: Biology, Function, and Translation. Am J Hum Genet. 2017; 101(1):5-22. PMC: 5501872. DOI: 10.1016/j.ajhg.2017.06.005. View

16.

Ho W, Tan M, Mavaddat N, Tai M, Mariapun S, Li J . European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Nat Commun. 2020; 11(1):3833. PMC: 7395776. DOI: 10.1038/s41467-020-17680-w. View

17.

Wang M, Menon R, Mishra S, Patel A, Chaffin M, Tanneeru D . Validation of a Genome-Wide Polygenic Score for Coronary Artery Disease in South Asians. J Am Coll Cardiol. 2020; 76(6):703-714. PMC: 7592606. DOI: 10.1016/j.jacc.2020.06.024. View

18.

Prive F, Aschard H, Carmi S, Folkersen L, Hoggart C, OReilly P . Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. Am J Hum Genet. 2022; 109(1):12-23. PMC: 8764121. DOI: 10.1016/j.ajhg.2021.11.008. View

19.

Hujoel M, Loh P, Neale B, Price A . Incorporating family history of disease improves polygenic risk scores in diverse populations. Cell Genom. 2022; 2(7). PMC: 9351615. DOI: 10.1016/j.xgen.2022.100152. View

20.

Hassanin E, Spier I, Bobbili D, Aldisi R, Klinkhammer H, David F . Clinically relevant combined effect of polygenic background, rare pathogenic germline variants, and family history on colorectal cancer incidence. BMC Med Genomics. 2023; 16(1):42. PMC: 9987090. DOI: 10.1186/s12920-023-01469-z. View